Literature DB >> 10982586

Laparoscopy and peritoneal cytology in the staging of pancreatic cancer.

R E Jimenez1, A L Warshaw, C Fernandez-Del Castillo.   

Abstract

Staging laparoscopy in patients with pancreatic cancer allows identification of metastatic disease which is beyond the resolution of computed tomography. Laparoscopic ultrasound, dissection, and/or peritoneal cytology may be used to enhance the sensitivity of the staging procedure. Our experience at Massachusetts General Hospital with staging laparoscopy and peritoneal cytology over the past 8 years (N = 239) reveals that approximately 30% of patients without metastases by computed tomography harbor occult metastatic disease at laparoscopy. Additionally, published series demonstrate accurate determination of resectability in greater than 75% of patients after staging laparoscopy. Staging laparoscopy in patients with pancreatic cancer allows optimization of resources and avoidance of unnecessary surgery.

Entities:  

Mesh:

Year:  2000        PMID: 10982586     DOI: 10.1007/s005340050148

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  18 in total

Review 1.  Indications for staging laparoscopy in pancreatic cancer.

Authors:  Antonella De Rosa; Iain C Cameron; Dhanwant Gomez
Journal:  HPB (Oxford)       Date:  2015-11-18       Impact factor: 3.647

2.  Role of staging laparoscopy in peri-pancreatic and hepatobiliary malignancy.

Authors:  Sebastien Gaujoux; Peter J Allen
Journal:  World J Gastrointest Surg       Date:  2010-09-27

3.  The implications of positive peritoneal lavage cytology in potentially resectable pancreatic cancer.

Authors:  Ryuji Yoshioka; Akio Saiura; Rintaro Koga; Junichi Arita; Nobuyuki Takemura; Yoshihiro Ono; Junji Yamamoto; Toshiharu Yamaguchi
Journal:  World J Surg       Date:  2012-09       Impact factor: 3.352

4.  Percutaneous Peritoneal Lavage for the Rapid Staging of Gastric and Pancreatic Cancer.

Authors:  Linda M Pak; Daniel G Coit; Anne A Eaton; Peter J Allen; Michael I D'Angelica; Ronald P DeMatteo; William R Jarnagin; Vivian E Strong; T Peter Kingham
Journal:  Ann Surg Oncol       Date:  2017-01-05       Impact factor: 5.344

5.  Prognostic impact of RT-PCR-based detection of peritoneal micrometastases in patients with pancreatic cancer undergoing curative resection.

Authors:  Kaitlyn J Kelly; Joyce Wong; Rebecca Gladdy; Kimberly Moore-Dalal; Yanghee Woo; Mithat Gonen; Murray Brennan; Peter Allen; Yuman Fong; Daniel Coit
Journal:  Ann Surg Oncol       Date:  2009-09-18       Impact factor: 5.344

6.  Clinical implications of peritoneal cytology in potentially resectable pancreatic cancer: positive peritoneal cytology may not confer an adverse prognosis.

Authors:  Suguru Yamada; Shin Takeda; Tsutomu Fujii; Shuji Nomoto; Naohito Kanazumi; Hiroyuki Sugimoto; Hideki Kasuya; Yasuhiro Kodera; Tetsuro Nagasaka; Satoshi Morita; Akimasa Nakao
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

7.  Clinical significance of telomerase activity in peritoneal disseminated cells: gastrointestinal cancers.

Authors:  Inna L Botchkina; David E Rivadeneira; Kevin Watkins; Martin S Karpeh; Galina I Botchkina
Journal:  Mol Med       Date:  2008 Jan-Feb       Impact factor: 6.354

8.  Implications of peritoneal lavage cytology in resectable left-sided pancreatic cancer.

Authors:  Yoshifumi Iwagami; Hidetoshi Eguchi; Hiroshi Wada; Yoshito Tomimaru; Naoki Hama; Koichi Kawamoto; Shogo Kobayashi; Masaki Mori; Yuichiro Doki; Hiroaki Nagano
Journal:  Surg Today       Date:  2014-07-01       Impact factor: 2.549

Review 9.  Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer.

Authors:  Victoria B Allen; Kurinchi Selvan Gurusamy; Yemisi Takwoingi; Amun Kalia; Brian R Davidson
Journal:  Cochrane Database Syst Rev       Date:  2016-07-06

Review 10.  Neoadjuvant strategies for pancreatic cancer.

Authors:  Francesco Polistina; Giuseppe Di Natale; Giorgio Bonciarelli; Giovanni Ambrosino; Mauro Frego
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.